Emmaus Life Sciences
Healthcare · 9 employees
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.
Funding history
- Series pre-seed — $110K — Jun 2022
- Series seed — $1.9M — Feb 2021
- Series seed — $3.8M — Oct 2020
- Series seed — $3.7M — Oct 2020
- Funding Round — Undisclosed — Oct 2020
Recent signals
- Dec 22, 2025: Emmaus Life Sciences Enters Exchange Agreement to Restructure Debt
- Dec 17, 2025: SEC 8-K (1.01): On December 17, 2025, Emmaus Life Sciences, Inc. entered into a Material Definitive Agreement through an Exchange Agreement with an individual, whereby the company agreed to issue 6,332,692 shares of common stock, valued at approximately $0.38 per share, and a convertible promissory note of $600,000. This agreement was made in exchange for the surrender of an outstanding convertible promissory note, currently due with a principal amount of $3,000,000, which bore interest at 10% per annum. The transaction signifies a strategic shift for Emmaus as it restructures its outstanding debt and adjusts its capital structure, aimed at strengthening its financial position.
- Jan 29, 2025: Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
- Jul 23, 2024: Emmaus Life Sciences Appoints Willis C. Lee as Chief Executive Officer
- Jun 30, 2022: Raised $110K in Series pre-seed
- Feb 16, 2021: Raised $1.9M in Series seed
- Oct 09, 2020: Raised $3.8M in Series seed
- Oct 07, 2020: Raised $3.7M in Series seed
See plans & pricing → Track Emmaus Life Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.